OpenAI Nears Astra AI Model Launch With Safety Focus 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Add as a preferred source on Google
SAN DIEGO, March 08, 2018 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended December 31, 2017, before the opening of trading on Thursday, March 15, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, March 15. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on development programs in the conference call and webcast.
Conference Call
To listen to the conference call, dial in approximately ten minutes before the scheduled call to (323) 994-2083 (preferred), or (800) 562-8369 (toll-free), and reference confirmation code 2848082. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 2848082. The call also will be available live and archived through the events page at www.vical.com.
Invited participants may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to [email protected] or by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by email at [email protected].
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, including antiviral and antifungal candidates in clinical development. Additional information on Vical is available at www.vical.com.
Contact:
Andrew Hopkins
(858) 646-1127
Website: www.vical.com
